•
Mar 31, 2022

AbCellera Q1 2022 Earnings Report

AbCellera reported strong Q1 2022 results, driven by revenue growth and advancements in drug discovery programs.

Key Takeaways

AbCellera announced financial results for the first quarter of 2022, with total revenue of $317 million and net earnings of $169 million. The company saw growth in program starts and molecules advancing into the clinic.

Total revenue was $317 million, compared to $203 million in Q1 2021.

Net earnings were $0.59 per share on a basic and $0.54 on a diluted basis.

Six program starts in the quarter, bringing the cumulative total to 84.

One new molecule advanced into the clinic, bringing the cumulative total to six.

Total Revenue
$317M
Previous year: $203M
+56.2%
EPS
$0.54
Previous year: $0.37
+45.9%
Discovery partners
36
Previous year: 29
+24.1%
Gross Profit
$272M
Previous year: $183M
+48.8%
Cash and Equivalents
$546M
Previous year: $686M
-20.4%
Free Cash Flow
$85.7M
Previous year: $106M
-19.1%
Total Assets
$1.59B
Previous year: $1.13B
+41.1%

AbCellera

AbCellera

AbCellera Revenue by Segment

Forward Guidance

No specific forward guidance was provided in the earnings report.

Revenue & Expenses

Visualization of income flow from segment revenue to net income